Article
Baseline P2Y12 reactivity, kidney function, and CYP2C19 genotype determine clopidogrel responsiveness in acute stroke.
Scientific reports - 19 May 2023
Lee Yi-Chung, Liao Yi-Chu, Lin Chun-Jen, Chung Chih-Ping
Abstract excerpt
Clopidogrel is the most-widely used platelet P2Y12-inhibitor for secondary-prevention of ischemic stroke. Platelet P2Y12 reactivity before and after inhibitors can be measured with blood sampling by commercialized system. We aimed to evaluate (1) whether high-on-clopidogrel platelet P2Y12 reactivity (HCPR) is associated with short-term vascular events and (2) the predictors of HCPR in acute stroke. The inclusion...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
